X. Yan - Mirati Therapeut Inc | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 7 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

H. Borghaei,F. de Marinis, D. Dumoulin, C. Reynolds, W. S. M. E. Theelen, I. Percent,V. Gutierrez Calderon,M. L. Johnson, A. Madroszyk-Flandin, E. B. Garon, K. He, D. Planchard,

ANNALS OF ONCOLOGYno. 1 (2024): 66-76

引用0浏览0WOS引用

LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)

H. Borghaei,M.L. Johnson, E.B. Garon, K. He, D. Planchard, M. Reck, S. Popat,R.S. Herbst, T.A. Leal, D. Dumoulin,F. de Marinis, C.H. Reynolds,

Annals of Oncology (2023): S1308-S1308

引用0浏览0引用

KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/ Metastatic KRASG12C-Mutated NSCLC

S. Gadgeel, P. A. Janne, A. I. Spira, S. -H. I. Ou, R. S. Heist, J. M. Pacheco, M. L. Johnson, J. K. Sabari, K. Leventakos, J. A. Mason, K. Velastegui,X. Yan,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S118-S118

引用0浏览0引用

43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

T.A. Leal, D. Berz, I. Rybkin,W.T. Iams, D. Bruno, C. Blakely,A. Spira,M. Patel, D.M. Waterhouse,D. Richards,A. Pham, R. Jotte,

ANNALS OF ONCOLOGY（2022）

引用30浏览0引用

LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

P.A. Jänne,E.F. Smit,F. de Marinis, J. Laskin,M. Domine Gomez, S. Gadgeel, M.C. Garassino,S. Lu, A.S. Spira, V. Kang,S. Roshan,X. Yan,

Immuno-Oncology and Technology (2022): 100360-100360

引用4浏览0引用

Sitravatinib (Sitra) In Combination With Nivolumab (Nivo) Demonstrates Clinical Activity In Checkpoint Inhibitor (Cpi) Naive, Platinum-Experienced Patients (Pts) With Advanced Or Metastatic Urothelial Carcinoma (Uc)

P. Msaouel, A. O. Siefker-Radtke,R. Sweis, S. Mao,J. E. Rosenberg, U. N. Vaishampayan,A. Rezazadeh Kalebasty,R. Pili, M. Bupathi,L. T. Nordquist,D. R. Shaffer, N. Davis,

Annals of Oncology（2020）

引用7浏览0引用

P2.01-14 Phase 3 Trial of Sitravatinib Plus Nivolumab vs Docetaxel for Treatment of NSCLC After Platinum-Based Chemoimmunotherapy

E. Nidhiry,T. Mekhail, E. Thara,M. Nagasaka, C. Chen, B.G. Gopurala, N. Campbell,K. Eaton, Y. Homsi, R. Yanagihara, R. Vaddepally,X. Yan,

JOURNAL OF THORACIC ONCOLOGY（2019）

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn